Tirzepatide Tirzepatide represents the next generation of weight loss medications
In contrast, later in 2023, a multisociety statement from gastroenterology and hepatology organizations, including the AGA, AASLD, ACG, ASGE, and NASPGHAN, advised against routine discontinuation of GLP-1 therapy, emphasizing individualized patient management and the use of point-of-care gastric ultrasound (POCUS) to assess aspiration risk [9]
Understanding these scenarios helps you make informed decisions about your health
In the phase 2 trial, the largest average rise was about 6.7 beats per minute at 24 weeks on the highest 12 mg dose, with rates declining again by weeks 36 to 48
However, these medications should be used under the guidance of a healthcare provider to avoid potential interactions with semaglutide and other medications the patient may be taking
Rev Toxicol